An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies.

Datos básicos

ENSAYO CLÍNICO CCS1477-02 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2025

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

CELLCENTRIC LTD

Cita

Compartir